Methicillin-resistant

Short description

Methicillin resistance refers to the ability of certain bacteria to resist methicillin and other related beta-lactam antibiotics.

Detailed description

Methicillin is a beta-lactam antibiotic. In cases of methicillin resistance, the target structures of the antibiotics are usually altered in such a way that many beta-lactam antibiotics can no longer be effective.
Methicillin-resistant Staphylococcus aureus (MRSA) is of particular medical significance. Infections caused by MRSA can be more difficult to treat because many beta-lactam antibiotics commonly used against S. aureus are ineffective. However, other suitable antibiotics are available for treatment.

Sep 2025

JAC Antimicrob Resist

Molecular landscape of methicillin-resistant Staphylococcus aureus strains in clinical infections from hospitals in Lagos, Nigeria

Autoren

Olalekan A et al.

Jul 2025

Diagn Microbiol Infect Dis

Surveillance of multidrug resistant methicillin-resistant and Panton-Valentine leukocidin positive Staphylococcus aureus in healthy carriers in Lambaréné, Gabon

Autoren

Gouleu CS et al.

Banner der WHO zur World AMR Awareness Week 2024

World AMR Awareness Week 2024, 18-24 November – Educate. Advocate. Act now.

Antimicrobial resistance (AMR) is one of the most urgent challenges facing global health and development. Described as a “creeping pandemic” by the G7 forum of leading economic nations, AMR occurs

Several mustard-coloured, spherical bacteria in the middle of much smaller blue-coloured blood cells.

Phage lysin compound HY-133: Start of clinical phase I “first-in-human” study to eliminate Staphylococcus aureus in the nasal microbiome

The novel active agent HY-133, which was developed by HYpharm and prepared for clinical trials in collaboration with the German Center for Infection Research (DZIF) and universities in Tübingen

Innovative Phage Lysin HY-133 enters phase I clinical study

HYpharm's innovative preventive agent HY-133 has reached the first clinical trial phase. HY-133 is specifically effective against the bacterial pathogen Staphylococcus aureus including multi-resistant

The photo shows a group of four researchers (three women and one man) in white lab coats in a laboratory.

Researchers decode new antibiotic agent

More and more bacterial pathogens are developing resistance. There is an increasing risk that current drugs will no longer be effective against infectious diseases. Scientists around the world are

Several silver-coloured bioreactors with many connecting tubes and control screens used for fermentation and production of active agents.

Clinical development of two antimicrobial agents funded by Else Kröner-Fresenius Foundation

The Else Kröner-Fresenius Foundation's ForTra gGmbH for Research Transfer—the largest medicine-funding foundation in Germany—supports the legally compliant production of new drug candidates for direct

Dec 2022

Pharmaceutics

Detailed description

More about “Methicillin-resistant”